{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:01:15Z","timestamp":1791903675931,"version":"4.3.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Peripheral artery disease (PAD) is a prevalent and debilitating complication of diabetes and obesity, yet it remains underrecognized and undertreated. Glucagon-like peptide-1 receptor agonists, such as semaglutide, have shown cardiovascular benefits, but their impact on peripheral vascular outcomes remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis to evaluate the effect of semaglutide on limb events (LEs) in individuals with type 2 diabetes and\/or overweight or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, 19 randomized controlled trials encompassing 51 557 participants were included. Major limb events, prespecified and reported as safety outcomes in the original trials, were defined a priori as the primary outcome of this meta-analysis, comprising revascularizations, amputations, and PAD progression. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Semaglutide significantly reduced the risk of LEs compared with control interventions (OR 0.70; 95% CI 0.60\u20130.82; P &amp;lt; 0.0001), with no heterogeneity across studies (I\u00b2 = 0%). Benefits were consistent across patient subgroups, in patients with diabetes (OR 0.70; 95% CI: 0.57\u20130.87; P = 0.001) or obesity (OR 0.71; 95% CI: 0.56\u20130.89; P = 0.003); oral formulation (0.71; 95% CI: 0.53\u20130.94; P = 0.02) or subcutaneous (0.68; 95% CI: 0.49\u20130.95; P = 0.02 and 0.71; 95% CI: 0.57\u20130.89; P = 0.003, for 1.0 and 2.4\u2005mg, respectively); and regardless of background SGLT2 inhibitor use. Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis suggests that semaglutide is associated with a significant reduction in major LEs across diverse populations and treatment settings, supporting a potential protective effect on limb-related vascular safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay summary<\/jats:title>\n                    <jats:p>This meta-analysis evaluates whether semaglutide can reduce the risk of peripheral artery disease (PAD) complications in people with diabetes or obesity. By analysing data from 19 randomized controlled trials involving over 51 000 participants, the findings highlight semaglutide\u2019s potential role in lowering the risk of amputations, revascularizations, and disease progression, beyond its established benefits on weight loss and glycaemic control.<\/jats:p>\n                    <jats:p>Key findings:Semaglutide reduced the risk of PAD-related events by about 30% compared with other treatments.The protective effect was consistent across patient subgroups, formulations (oral or injectable), and irrespective of concomitant SGLT2 inhibitor use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag077","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:47:35Z","timestamp":1770295655000},"source":"Crossref","is-referenced-by-count":8,"title":["Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-1235","authenticated-orcid":false,"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples 80131 ,","place":["Italy"]},{"name":"Division of Clinical Cardiology, A.O.R.N. Sant'Anna e San Sebastiano , Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1196-7582","authenticated-orcid":false,"given":"Vincenzo","family":"Acerbo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples 80131 ,","place":["Italy"]},{"name":"Division of Clinical Cardiology, A.O.R.N. Sant'Anna e San Sebastiano , Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Life Science, Health, and Health Professions, Link Campus University , Rome ,","place":["Italy"]},{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Piazza Miraglia 2, Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Antonucci","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Rome 00133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ida","family":"Maiorino","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Piazza Miraglia 2, Naples ,","place":["Italy"]},{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Monaco","sequence":"additional","affiliation":[{"name":"Division of Clinical Cardiology, A.O.R.N. Sant'Anna e San Sebastiano , Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, University of Tor Vergata , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Giudice","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, A.O.R.N. \u2018Sant'Anna e San Sebastiano\u2019 , Caserta ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Piazza Miraglia 2, Naples ,","place":["Italy"]},{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-2678","authenticated-orcid":false,"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-5194","authenticated-orcid":false,"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Rome 00133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples 80131 ,","place":["Italy"]},{"name":"Division of Clinical Cardiology, A.O.R.N. Sant'Anna e San Sebastiano , Caserta 81100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2026022010364742100_zwag077-B1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"The Lancet"},{"key":"2026022010364742100_zwag077-B2","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"2026022010364742100_zwag077-B3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: molecular mechanisms and therapeutic strategies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026022010364742100_zwag077-B4","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026022010364742100_zwag077-B5","doi-asserted-by":"crossref","first-page":"e006399","DOI":"10.1161\/CIRCOUTCOMES.119.006399","article-title":"Incidence and factors associated with major amputation in patients with peripheral artery disease","volume":"13","author":"Long","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026022010364742100_zwag077-B6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022010364742100_zwag077-B7","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026022010364742100_zwag077-B8","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B9","doi-asserted-by":"crossref","first-page":"108906","DOI":"10.1016\/j.jdiacomp.2024.108906","article-title":"Exploring the antioxidant properties of semaglutide: a comprehensive review","volume":"38","author":"Yaribeygi","year":"2024","journal-title":"J Diabetes Complications"},{"key":"2026022010364742100_zwag077-B10","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"The Lancet"},{"key":"2026022010364742100_zwag077-B13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.phrs.2016.11.016","article-title":"Disruption of mitochondrial quality control in peripheral artery disease: new therapeutic opportunities","volume":"115","author":"Ueta","year":"2017","journal-title":"Pharmacol Res"},{"key":"2026022010364742100_zwag077-B14","doi-asserted-by":"crossref","first-page":"H867","DOI":"10.1152\/ajpheart.00690.2021","article-title":"Impaired microcirculatory function, mitochondrial respiration, and oxygen utilization in skeletal muscle of claudicating patients with peripheral artery disease","volume":"322","author":"Park","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026022010364742100_zwag077-B15","doi-asserted-by":"crossref","first-page":"e1379189","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2026022010364742100_zwag077-B16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B17","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2026022010364742100_zwag077-B18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B19","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"2026022010364742100_zwag077-B20","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2026022010364742100_zwag077-B21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022010364742100_zwag077-B23","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"2026022010364742100_zwag077-B24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B25","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026022010364742100_zwag077-B27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026022010364742100_zwag077-B28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026022010364742100_zwag077-B29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022010364742100_zwag077-B30","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022010364742100_zwag077-B31","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022010364742100_zwag077-B32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s13679-023-00510-7","article-title":"Obesity and peripheral artery disease: current evidence and controversies","volume":"12","author":"Lempesis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2026022010364742100_zwag077-B33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coph.2018.03.001","article-title":"Glucose-lowering treatment in cardiovascular and peripheral artery disease","volume":"39","author":"Suades","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"2026022010364742100_zwag077-B34","doi-asserted-by":"crossref","first-page":"1396656","DOI":"10.3389\/fphar.2024.1396656","article-title":"Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026022010364742100_zwag077-B35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026022010364742100_zwag077-B36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12891-024-07640-6","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Musculoskelet Disord"},{"key":"2026022010364742100_zwag077-B37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/ATVBAHA.124.320195","article-title":"Peripheral artery disease: molecular mechanisms and novel therapies","volume":"44","author":"Athavale","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026022010364742100_zwag077-B38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/biom15050612","article-title":"Understanding the role of adipokines in cardiometabolic dysfunction: a review of current knowledge","volume":"15","author":"Datta","year":"2025","journal-title":"Biomolecules"},{"key":"2026022010364742100_zwag077-B39","first-page":"369369","article-title":"Matrix metallopeptidase 9 contributes to the beginning of plaque and is a potential biomarker for the early identification of atherosclerosis in asymptomatic patients with diabetes","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026022010364742100_zwag077-B40","doi-asserted-by":"crossref","first-page":"e1365183","DOI":"10.3389\/fmed.2024.1365183","article-title":"Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities","volume":"11","author":"Sarzani","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026022010364742100_zwag077-B41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.athplu.2022.05.004","article-title":"Semaglutide treatment attenuates vessel remodelling in ApoE-\/- mice following vascular injury and blood flow perturbation","volume":"49","author":"Jensen","year":"2022","journal-title":"Atheroscler Plus"},{"key":"2026022010364742100_zwag077-B42","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2026022010364742100_zwag077-B43","doi-asserted-by":"crossref","first-page":"110196","DOI":"10.1016\/j.intimp.2023.110196","article-title":"Semaglutide alleviates inflammation-induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes","volume":"119","author":"Pan","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2026022010364742100_zwag077-B44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-024-02541-3","article-title":"NLRP3 inflammasome-modulated angiogenic function of EPC via PI3K\/Akt\/mTOR pathway in diabetic myocardial infarction","volume":"24","author":"Li","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026022010364742100_zwag077-B45","doi-asserted-by":"crossref","first-page":"110688","DOI":"10.1016\/j.diabres.2023.110688","article-title":"Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes","volume":"200","author":"Longo","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026022010364742100_zwag077-B46","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"2026022010364742100_zwag077-B47","doi-asserted-by":"crossref","first-page":"e241545","DOI":"10.1001\/jamanetworkopen.2024.1545","article-title":"Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease","volume":"7","author":"Caruso","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026022010364742100_zwag077-B48","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf697","article-title":"Comprehensive risk factor control in Type 2 diabetes and incident peripheral artery disease","author":"Yu","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026022010364742100_zwag077-B49","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1111\/dom.16594","article-title":"Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: an observational study comparing matched cohorts","volume":"27","author":"Caruso","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026022010364742100_zwag077-B50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-017-0611-x","article-title":"Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?","volume":"16","author":"Tanaka","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2026022010364742100_zwag077-B51","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"2026022010364742100_zwag077-B52","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jvs.2022.12.015","article-title":"The global burden of peripheral artery disease","volume":"77","author":"Eid","year":"2023","journal-title":"J Vasc Surg"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag077\/66822185\/zwag077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag077\/66822185\/zwag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:37:03Z","timestamp":1771601823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag077\/8469561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag077","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"zwag077"}}